Global GERD Market Growth, Share, Size, Trends and Forecast (2025 - 2031)
By Administration Route;
Oral and Parenteral.By Drug Type;
Proton Pump Inhibitors (PPIs), H2 Receptor Blockers, and Others.By Diagnosis;
Upper Endoscopy, Ambulatory Acid (pH) Probe Test, Esophageal Manometry, and Others.By Geography;
North America, Europe, Asia Pacific, Middle East and Africa, and Latin America - Report Timeline (2021 - 2031).Introduction
Global GERD Market (USD Million), 2021 - 2031
In the year 2024, the Global GERD Market was valued at USD 5,413.00 million. The size of this market is expected to increase to USD 6,098.08 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 1.7%.
The global GERD (Gastroesophageal Reflux Disease) market is experiencing steady growth, driven by the increasing prevalence of GERD, changes in lifestyle, dietary habits, and the rising awareness about the condition. GERD is becoming more common due to factors like obesity, smoking, and poor eating habits, leading to a surge in demand for treatments such as proton pump inhibitors (PPIs), H2 receptor blockers, and other medications. The market is also witnessing advancements in minimally invasive surgical procedures and endoscopic treatments, offering patients new options for managing severe cases of GERD. As more people are diagnosed with GERD, there is a corresponding rise in demand for both pharmaceutical and surgical interventions.
North America holds the largest market share, owing to the high prevalence of GERD in the United States and Canada, along with the presence of advanced healthcare infrastructure and a wide range of treatment options. Europe follows closely behind, with countries like Germany, France, and the UK showing significant demand for GERD treatments. However, the Asia-Pacific region is emerging as a high-growth market, driven by urbanization, dietary changes, and increasing healthcare access in countries such as China and India. The expanding middle class and rising awareness about GERD in these regions create a favorable environment for market growth, while Latin America and the Middle East & Africa are also gradually witnessing a rise in the demand for GERD treatments due to improving healthcare infrastructure.
Despite the positive growth outlook, the GERD market faces challenges such as high treatment costs in developing regions, particularly for advanced therapies and surgeries. Additionally, the long-term use of GERD medications, such as PPIs, raises concerns about safety and side effects, leading to growing interest in alternative treatments. However, emerging opportunities in the market include the expansion of healthcare infrastructure in developing regions, which provides greater access to GERD treatments, and innovations in drug development and surgical procedures. As more people gain access to affordable and effective therapies, the GERD market is expected to continue evolving, with significant advancements in both pharmacological and surgical treatments.
Global GERD Market Recent Developments
-
In July 2024, Phathom Pharmaceuticals secured an additional indication for its acid suppression drug. The FDA expanded Voquezna’s label to include relief from heartburn associated with non,erosive gastroesophageal reflux disease.
-
New GERD devices cannot reach the market sooner due to drawn,out approval processes caused by strict regulatory regulations and the demand for extensive clinical data. This acts as an impediment to gastroesophageal reflux disease (GERD) device market expansion.
Segment Analysis
The Global GERD Market has been segmented by Administration Route, Drug Type, Diagnosis and Geography, driven by rising prevalence due to lifestyle changes, obesity, and an aging population. By administration route, the market is segmented into oral, parenteral, and others. Oral administration dominates the market due to its convenience and patient compliance, with products like proton pump inhibitors (PPIs) and H2 receptor antagonists being commonly prescribed. Parenteral administration, although less common, is utilized in hospital settings for severe cases requiring rapid intervention.
In terms of dosage form, the market is divided into tablets, capsules, liquid formulations, and others. Tablets and capsules account for the majority of the market share because of their ease of use and stability. Liquid formulations are particularly important for pediatric and geriatric patients, offering an alternative for those who have difficulty swallowing pills. Innovations in drug delivery systems, such as sustained-release formulations, aim to enhance treatment efficacy and improve patient adherence.
Geographically, the GERD market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. North America holds the largest market share, driven by a high prevalence of GERD and well-established healthcare infrastructure. Europe follows closely, with increasing awareness and advancements in diagnostic tools contributing to market growth. The Asia-Pacific region is anticipated to witness the fastest growth due to rising healthcare expenditure, urbanization, and growing awareness of gastrointestinal health. Latin America and the Middle East and Africa are emerging markets, where improving access to healthcare and increasing diagnosis rates are expected to drive demand.
Global GERD Segment Analysis
In this report, the Global GERD Market has been segmented by Administration Route, Drug Type, Diagnosis and Geography.
Global GERD Market, Segmentation by Administration Route
The Global GERD Market has been segmented by Administration Route into Oral and Parenteral.
The global GERD (Gastroesophageal Reflux Disease) market, segmented by administration route, is predominantly driven by oral administration, which accounts for the largest market share. Oral administration is the most preferred and convenient method for the treatment of GERD, offering ease of use and good patient compliance. Oral dosage forms, including tablets, capsules, and liquid formulations, are widely prescribed for the management of GERD. Proton pump inhibitors (PPIs), H2 receptor antagonists, and antacids are commonly available in oral formulations, offering effective relief from the symptoms of GERD by reducing stomach acid production and improving esophageal healing.
Parenteral administration, while less common in the treatment of GERD, plays an essential role in severe or acute cases, particularly in hospitalized patients. Parenteral routes, such as intravenous (IV) administration, are used to provide rapid symptom relief and control in patients with severe reflux esophagitis or those who are unable to take oral medications due to swallowing difficulties. The parenteral route allows for immediate drug absorption and is typically used in critical care settings, where fast and efficient symptom management is necessary.
The preference for oral over parenteral administration in the GERD market can be attributed to the convenience, cost-effectiveness, and patient compliance associated with oral treatments. As a result, oral medications continue to dominate the market, and innovations in formulation design, such as extended-release tablets and combination therapies, are expected to enhance patient outcomes and further solidify the position of oral administration. However, the parenteral route's role remains vital for acute and severe GERD cases, particularly in hospital settings where swift intervention is crucial for patient stabilization and recovery.
Global GERD Market, Segmentation by Drug Type
The Global GERD Market has been segmented by Drug Type into Proton Pump Inhibitors (PPIs), H2 Receptor Blockers, and Others.
The global GERD market is primarily segmented by drug type, with Proton Pump Inhibitors (PPIs) dominating the market share. PPIs are the most commonly prescribed medication for GERD due to their effectiveness in reducing stomach acid production and providing long-term relief from symptoms. They are typically used in the treatment of moderate to severe GERD cases and are considered the first-line therapy. PPIs such as omeprazole, esomeprazole, and lansoprazole are widely available and have a strong presence in both prescription and over-the-counter markets.
The H2 receptor blockers segment includes drugs like ranitidine, famotidine, and cimetidine, which work by blocking histamine receptors in the stomach, thus reducing acid production. While not as potent as PPIs, H2 blockers are often used for mild to moderate cases of GERD. They are also widely available over-the-counter, making them a preferred choice for individuals seeking quick relief from occasional acid reflux. Despite their availability, the use of H2 blockers has been slightly overshadowed by PPIs, which offer more effective and long-lasting results for chronic GERD sufferers.
The Others segment of the GERD market includes a variety of treatments such as antacids, prokinetic agents, and mucosal protectants. Antacids like calcium carbonate and magnesium hydroxide are used for quick relief from acid reflux symptoms, but they do not offer long-term solutions. Prokinetic agents, which help improve esophageal motility and gastric emptying, are used in some GERD patients, particularly those with impaired gastric emptying. Mucosal protectants like sucralfate help protect the esophagus lining from acid damage but are less commonly used compared to PPIs and H2 blockers. These alternative therapies contribute to a smaller, yet significant portion of the GERD drug market.
Global GERD Market, Segmentation by Diagnosis
The Global GERD Market has been segmented by Diagnosis into Upper Endoscopy, Ambulatory Acid (pH) Probe Test, Esophageal Manometry, and Others.
The global GERD (Gastroesophageal Reflux Disease) market, segmented by diagnosis, reveals a variety of diagnostic tools that cater to different levels of severity and clinical needs. The upper endoscopy is one of the most commonly used diagnostic methods. It involves visualizing the esophagus and stomach using a flexible tube with a camera, allowing physicians to detect complications such as esophagitis, ulcers, or strictures. Upper endoscopy is often recommended for patients with persistent GERD symptoms, those with complications, or individuals at higher risk of developing esophageal cancer, providing clear insights into the severity of the disease.
The ambulatory acid (pH) probe test is another essential diagnostic tool in the GERD market, especially for evaluating the frequency and duration of acid reflux episodes over a 24- to 48-hour period. This test involves placing a small probe in the esophagus to measure pH levels, which helps in confirming the diagnosis of GERD when symptoms do not align with other findings. It is particularly useful for patients with atypical symptoms, such as chest pain or hoarseness, and for assessing the effectiveness of GERD treatments. The ability to monitor acid reflux in real-time is a key factor driving the adoption of this diagnostic method.
Esophageal manometry is a more specialized diagnostic technique used to evaluate the function of the lower esophageal sphincter (LES) and esophageal motility. This test is often used to rule out other conditions that may mimic GERD, such as achalasia or other esophageal motility disorders. While not as commonly used as upper endoscopy or pH testing, esophageal manometry provides valuable insights for determining the underlying causes of GERD symptoms. The "Others" category includes less invasive or more novel diagnostic methods such as esophageal impedance testing, capsule endoscopy, and MRI-based imaging techniques. Each diagnostic method plays a crucial role in diagnosing GERD accurately and tailoring treatment strategies based on the severity and characteristics of the disease.
Global GERD Market, Segmentation by Geography
In this report, the Global GERD Market has been segmented by Geography into five regions; North America, Europe, Asia Pacific, Middle East and Africa and Latin America.
Global GERD Market Share (%), by Geographical Region, 2024
The global GERD market is dominated by North America, which holds the largest market share, primarily driven by high prevalence rates of GERD and strong healthcare infrastructure. The United States, in particular, accounts for a substantial portion of the market due to the widespread use of GERD medications, advanced treatment options, and increased awareness of the disease. Additionally, the high adoption of proton pump inhibitors (PPIs) and the availability of over-the-counter medications further boost the market in this region. The aging population, combined with rising obesity rates, continues to contribute to the growing demand for GERD treatments.
Europe follows closely behind North America in terms of market share. Countries like Germany, France, and the United Kingdom experience a high incidence of GERD, which drives demand for both prescription and over-the-counter medications. The European market benefits from a well-established healthcare system and increasing awareness about GERD, leading to more frequent diagnoses and treatment regimens. However, the market growth in Europe is somewhat slower compared to North America due to regulatory constraints and a higher emphasis on cost-effective treatments, including generic medications.
The Asia-Pacific (APAC) region is experiencing rapid growth in the GERD market, capturing an increasing share due to factors like urbanization, changing diets, and growing healthcare access in countries such as China, India, and Japan. With rising awareness of gastrointestinal disorders, the demand for GERD treatments is expected to surge. Additionally, the increasing adoption of lifestyle modifications and medications is contributing to this growth. While the market share in APAC is still smaller compared to North America and Europe, its growth potential is significant, driven by the expanding middle class and improvements in healthcare infrastructure. Similarly, Latin America and Middle East & Africa (MEA) are gradually gaining traction, with expanding healthcare access and growing awareness leading to a steady increase in GERD treatment adoption.
Market Trends
This report provides an in depth analysis of various factors that impact the dynamics of Global GERD Market. These factors include; Market Drivers, Restraints and Opportunities Analysis.
Drivers, Restraints and Opportunity Analysis
Drivers
- Increasing prevalence of GERD
- Rising demand for GERD medications
- Growing awareness and early diagnosis
- Advancements in surgical treatments:
Advancements in surgical treatments for GERD have significantly contributed to the growth of the global GERD market by providing more effective, minimally invasive solutions for patients who do not respond to medication. One of the key developments is the evolution of laparoscopic surgery, particularly fundoplication, a procedure where the top of the stomach is wrapped around the esophagus to prevent acid reflux. This procedure has seen improvements over the years, offering reduced recovery times, fewer complications, and greater precision. As a result, more patients with severe GERD are opting for surgical intervention, driving demand for advanced surgical treatments.
The introduction of endoscopic treatments has also expanded the options available for GERD patients, making surgeries less invasive and more accessible. Technologies like transoral incisionless fundoplication (TIF) allow surgeons to perform the procedure through the mouth, eliminating the need for external incisions. These minimally invasive techniques not only reduce recovery time but also offer patients a quicker return to daily activities. Endoscopic therapies have provided an alternative to traditional surgery, particularly for patients who are not candidates for more invasive procedures due to health conditions or other concerns.
Furthermore, the development of magnetic sphincter augmentation (MSA), such as the LINX device, has added a new dimension to GERD treatment. The LINX device consists of a small ring of magnets that is placed around the lower esophageal sphincter to prevent acid reflux. This approach is particularly beneficial for patients who experience reflux despite taking medications, offering a reversible and less invasive option compared to traditional surgery. With these advancements, the global GERD market is experiencing increased adoption of surgical treatments, offering patients a range of options that improve outcomes and quality of life, thereby expanding the overall market for GERD therapies.
Restraints
- Side effects and long-term safety concerns
- Availability of alternative treatments
- High treatment costs in developing regions:
One of the significant restraints on the global GERD market is the high treatment costs in developing regions, which limit access to advanced GERD therapies. In many low- and middle-income countries, the cost of prescription medications, particularly proton pump inhibitors (PPIs) and other specialized treatments, is a major barrier for a large portion of the population. These medications are often out of reach for individuals without adequate insurance coverage or disposable income, leading to delays in treatment or reliance on less effective over-the-counter medications. The inability to access effective treatment results in worsened health outcomes and more severe cases of GERD, putting pressure on healthcare systems.
The high costs associated with surgical treatments, such as laparoscopic fundoplication or endoscopic procedures like transoral incisionless fundoplication (TIF), further exacerbate the issue in developing regions. These procedures require specialized equipment, skilled surgeons, and extended hospital stays, which drive up overall treatment expenses. In countries with underdeveloped healthcare infrastructure, the availability of these advanced treatments is often limited, and patients may be forced to seek care abroad, incurring additional costs. This creates a significant disparity in access to effective GERD management, where those who cannot afford the treatments continue to suffer from chronic symptoms.
Additionally, the lack of healthcare insurance coverage in many developing regions contributes to the financial burden of GERD treatments. Even when treatments are available, the high out-of-pocket costs for medications and procedures discourage individuals from seeking timely care. In countries where public healthcare systems are overwhelmed or underfunded, the costs associated with GERD treatment are often passed on to patients, making it a financial strain. This constraint limits the potential market for GERD treatments in these regions, as individuals prioritize other health concerns or delay treatment until symptoms become severe, leading to higher healthcare costs in the long term.
Opportunities
- Development of novel therapeutics
- Adoption of telemedicine and online pharmacies
- Focus on personalized medicine
- Expanding healthcare infrastructure in emerging markets:
One of the significant opportunities in the global GERD market is the expanding healthcare infrastructure in emerging markets. As economies in regions like Asia-Pacific, Latin America, and the Middle East grow, governments are increasingly investing in healthcare infrastructure to improve access to medical care. This expansion includes building more hospitals, increasing the availability of healthcare professionals, and improving diagnostic capabilities, which directly benefits the treatment of conditions like GERD. With better access to healthcare facilities, there is a greater potential for earlier diagnosis and more widespread adoption of GERD treatments, thus driving market growth in these regions.
As the healthcare infrastructure in emerging markets continues to improve, there is also a growing opportunity to introduce advanced GERD treatments to these regions. Many of these countries are seeing an increase in the prevalence of lifestyle-related diseases, including GERD, due to changing diets, urbanization, and sedentary lifestyles. As healthcare systems become more sophisticated, there is an increasing demand for both over-the-counter and prescription medications, as well as more advanced treatments such as endoscopic procedures and minimally invasive surgeries. Pharmaceutical companies and medical device manufacturers can seize this opportunity by introducing affordable and accessible GERD solutions tailored to local needs and preferences.
Moreover, the rise in health insurance coverage in emerging markets presents another opportunity for the GERD market. As healthcare becomes more accessible through public and private insurance schemes, more people will be able to afford GERD medications and treatments. Insurance schemes, particularly in rapidly developing economies, are beginning to cover a broader range of therapies, including preventive care and advanced surgical options. This trend is expected to accelerate market growth, as more individuals in emerging markets will be able to seek timely and effective treatment for GERD, leading to better health outcomes and a larger customer base for GERD-related products and services.
Competitive Landscape Analysis
Key players in Global GERD Market include,
- AstraZeneca
- Eisai
- GSK
- Johnson & Johnson
- Takeda
In this report, the profile of each market player provides following information:
- Company Overview and Product Portfolio
- Key Developments
- Financial Overview
- Strategies
- Company SWOT Analysis
- Introduction
- Research Objectives and Assumptions
- Research Methodology
- Abbreviations
- Market Definition & Study Scope
- Executive Summary
- Market Snapshot, By Administration Route
- Market Snapshot, By Drug Type
- Market Snapshot, By Diagnosis
- Market Snapshot, By Region
- Global GERD Market Dynamics
- Drivers, Restraints and Opportunities
- Drivers
-
Increasing prevalence of GERD
-
Rising demand for GERD medications
-
Growing awareness and early diagnosis
-
Advancements in surgical treatments
-
- Restraints
- Side effects and long-term safety concerns
- Availability of alternative treatments
- High treatment costs in developing regions
- Opportunities
- Development of novel therapeutics
- Adoption of telemedicine and online pharmacies
- Focus on personalized medicine
- Expanding healthcare infrastructure in emerging markets
- Drivers
- PEST Analysis
- Political Analysis
- Economic Analysis
- Social Analysis
- Technological Analysis
- Porter's Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitutes
- Threat of New Entrants
- Competitive Rivalry
- Drivers, Restraints and Opportunities
- Market Segmentation
- Global GERD Market, By Administration Route, 2021 - 2031 (USD Million)
- Oral
- Parenteral
- Global GERD Market, By Drug Type, 2021 - 2031 (USD Million)
- Proton Pump Inhibitors (PPIs)
- H2 Receptor Blockers
- Others
- Global GERD Market, By Diagnosis, 2021 - 2031 (USD Million)
- Upper Endoscopy
- Ambulatory Acid (pH) Probe Test
- Esophageal Manometry
- Others
- Global GERD Market, By Geography, 2021 - 2031 (USD Million)
- North America
- United States
- Canada
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Nordic
- Benelux
- Rest of Europe
- Asia Pacific
- Japan
- China
- India
- Australia & New Zealand
- South Korea
- ASEAN (Association of South East Asian Countries)
- Rest of Asia Pacific
- Middle East & Africa
- GCC
- Israel
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- North America
- Global GERD Market, By Administration Route, 2021 - 2031 (USD Million)
- Competitive Landscape
- Company Profiles
- AstraZeneca
- Eisai
- GSK
- Johnson & Johnson
- Takeda
- Company Profiles
- Analyst Views
- Future Outlook of the Market